The debate continues about the protective effect of eyeglasses against contracting the COVID-19 virus. Researchers from Denmark reported that their results were inconclusive regarding whether wearing eyeglasses is linked with a decreased risk of COVID-19 infections.
The research points to the importance of isolating offending organism.
The guidance comes as a result of an increase in eye injury.
Oyster Point Pharma Inc. announced that the largest Medicare pharmacy benefit manager in the United States will add its varenicline solution nasal spray for the treatment of dry eye.
A meta-analysis has found that depression and anxiety are significantly correlated with dry eye disease symptoms but not to dry eye disease signs.
A literature review finds that glaucoma care changed for the better during the COVID-19 pandemic.
New research examines the disparities in vision loss in glaucoma cases.
Cimerli can be used for all 5 indications. No information on pricing has been released.
Oyster Point Pharma Inc. this week announced the expansion of patient access to varenicline solution (Tyrvaya) nasal spray.
Research examines whether a step-approach with treatment for macular edema produces positive results.
The pipeline for eye health is full of potential therapies. Here's a look at 4 that may be available in the near future.
The price of the biosimilar may also be persuasive for patients.
The drug is a potential new therapy for dry eye disease with a novel mechanism of action.
The FDA has accepted the supplemental Biologics License Application of aflibercept injection for review in patients with diabetic retinopathy.
The CLEAR Act would clarify the FDA’s authority to regulate products, including eye drops, after a court decision created unnecessary confusion and turmoil.
A team of investigators has found that there is a bidirectional association between chronic kidney disease and glaucoma.
As dexamethasone adds indications, a study confirms efficacy of punctal occlusion for allergic conjunctivitis.
Research highlights link between impaired vision and mental health in children.
Eyelid ptosis can be treated with α-adrenergic eye drops.
The biosimilar has a list price 40% less than its reference product.
A new report from the CDC that examined 20-year trends in vision impairment among patients with diabetes, which suggests the rate of decline in vision impairment began to plateau in 2012 and may be on the rise in recent years.
The Focus on Diabetes program will be sharing resources through the end of the month.
Researchers may have identified a potential solution.
Asthma may increase a person’s risk of developing dry eye disease.
Medications like inhalers and nasal sprays can be challenging for patients to administer correctly.
